

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72779

**Title:** Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03029494

**Position:** Associate Editor

**Academic degree:** DSc, FEBG, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Canada

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-10-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-30 03:23

**Reviewer performed review:** 2021-10-30 13:56

**Review time:** 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a very basic review on technical processes and approvals of the biosimilars worldwide. Authors did not make a thorough effort to update us on most recent data, exposures and market shares of biosimilar sales worldwide, neither on the use or mandatory use (tender systems) around the globe, non-medical switch, nocebo effect etc. Most of the data highlighted are textbook style, the authors are clearly not expert in the field of biologics/biosimilars in IBD and did not make an effort to read and digest the available literature, thus the paper lacks novelty and practical conclusion for the clinicians. It is complete rewriting and restructuring that the paper needs.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72779

**Title:** Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03249854

**Position:** Editorial Board

**Academic degree:** FASCRS, MD

**Professional title:** Chief Doctor, Director, Professor, Surgeon

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-10-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-11-03 02:25

**Reviewer performed review:** 2021-11-05 06:43

**Review time:** 2 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

I am honored to learn about the emerging role of biosimilars in the clinical care of IBD patients through this manuscript. With the global increase in IBD incidence, traditional drugs can no longer meet the standard treatment pursued by IBD. The advent of the era of biologics, especially anti-TNF-  $\alpha$ , offers first-line treatment options. However, inevitable problems ensued, such as the loss of response of biologics, the increase in hospitalization rates, the financial burden of patients and psychological stress. Compared with the original research drug, biosimilars are highly similar in clinical behavior and product quality, whether they can be safe and effective alternative, popularized and used in clinical practice, the content discussed in this article has a certain practical significance. One suggestion is to highlight the advantages of biosimilars in the market competition. From a small level, it is to reduce the burden of patient care. On a large level, not only to make the pharmaceutical industry the fittest, but also to improve the use of NHS funds. In the future, we look forward to a safe and effective conclusion from large sample studies. It is hoped that through this article, biosimilars will be understood and publicized by doctors and patients, recognized and supported by insurance companies and government policies. The above is my personal opinion, if it is helpful to you please adopt it.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72779

**Title:** Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05487696

**Position:** Peer Reviewer

**Academic degree:** MD, MSc

**Professional title:** Consultant Physician-Scientist, Doctor, Lecturer

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-10-27

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2022-02-07 08:56

**Reviewer performed review:** 2022-02-07 09:00

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

Well-written